Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase 3 2Phase 1/2 2

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Has results × necitumumab × Clear all
NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Eli Lilly and Company

Phase 1 Completed
29 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02451930 2020-10-05

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Eli Lilly and Company

Phase 1 Completed
71 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02411591 2020-07-09

A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 1 Completed
66 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01088464 2017-02-03

Study of IMC-11F8 in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
15 enrolled 22 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡